CY1112655T1 - Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις - Google Patents

Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις

Info

Publication number: CY1112655T1
Authority: CY; Cyprus
Prior art keywords: polypeptides; well; relates; preparation; cells
Prior art date: 2005-07-20

Application number

CY20121100161T

Other languages

Greek (el)

English (en)

Inventor

Michel Morre

Brigitte Assouline

Iann Rance

Anne Gregoire

Corinne Breque

Original Assignee

Cytheris

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-07-20

Filing date

2012-02-16

Publication date

2016-02-10

2012-02-16 Application filed by Cytheris filed Critical Cytheris

2016-02-10 Publication of CY1112655T1 publication Critical patent/CY1112655T1/el

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5418—IL-7
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Virology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Transplantation (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CY20121100161T 2005-07-20 2012-02-16 Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις CY1112655T1 (el)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP05291556A EP1746161A1 (fr)	2005-07-20	2005-07-20	IL-7 glycosylée, préparation et utilisations
EP06795556A EP1904635B1 (fr)	2005-07-20	2006-07-19	Il-7 glycosylee, preparation et utilisations

Publications (1)

Publication Number	Publication Date
CY1112655T1 true CY1112655T1 (el)	2016-02-10

Family

ID=35385570

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CY20121100161T CY1112655T1 (el)	2005-07-20	2012-02-16	Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις

Country Status (19)

Country	Link
US (3)	US7708985B2 (fr)
EP (2)	EP1746161A1 (fr)
JP (2)	JP5685363B2 (fr)
CN (2)	CN105647939A (fr)
AT (1)	ATE542901T1 (fr)
AU (1)	AU2006271315B2 (fr)
CA (2)	CA2615562C (fr)
CY (1)	CY1112655T1 (fr)
DK (1)	DK1904635T3 (fr)
EA (1)	EA012802B1 (fr)
ES (1)	ES2379732T3 (fr)
IL (1)	IL188480A0 (fr)
NO (1)	NO344802B1 (fr)
NZ (1)	NZ564907A (fr)
PL (1)	PL1904635T3 (fr)
PT (1)	PT1904635E (fr)
SI (1)	SI1904635T1 (fr)
WO (1)	WO2007010401A2 (fr)
ZA (1)	ZA200800533B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2367891T3 (es)	2000-09-29	2011-11-10	Schering Corporation	Interleucina-10 pegilada.
EP1391513A1 (fr)	2002-08-08	2004-02-25	Cytheris	Substance médicamenteuse IL-7, composition comprenant IL-7, procédé de sa préparation et ses utilisations
DK1699822T3 (da)	2003-12-30	2008-08-04	Merck Patent Gmbh	IL-7-fusionsproteiner med antistofdele, fremstilling deraf og anvendelse deraf
EP2066336B1 (fr)	2006-09-28	2012-09-19	Merck Sharp & Dohme Corp.	Utilisation d'il-10 pégilée pour traiter un cancer
CL2007003411A1 (es) *	2006-11-28	2008-07-04	Centelion	Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
CN101943688B (zh) *	2009-07-10	2013-01-02	复旦大学	一种利用质谱靶板富集糖基化肽段的方法
EP2808344A1 (fr)	2010-06-01	2014-12-03	Monash University	Anticorps dirigés contre le récepteur tyrosine kinase c-Met
NZ707637A (en) *	2010-07-19	2016-09-30	Otago Innovation Ltd	Signal biomarkers
AU2011325871B2 (en)	2010-11-05	2016-02-04	Medvet Science Pty Ltd	Markers of endothelial progenitor cells and uses thereof
CA2820956C (fr) *	2010-12-10	2016-05-03	University Of Central Florida Research Foundation, Inc.	Methodes et compositions comprenant des ligands du recepteur a l'il-7
EP2739301B1 (fr)	2011-08-03	2016-01-20	Cytheris	Immunothérapie contre le vhc
RU2679889C2 (ru)	2013-04-18	2019-02-14	Армо Байосайенсиз, Инк.	Способы применения интерлейкина-10 для лечения заболеваний и расстройств
US9823255B2 (en)	2013-06-17	2017-11-21	Armo Biosciences, Inc.	Method for assessing protein identity and stability
CN105848674A (zh)	2013-11-11	2016-08-10	阿尔莫生物科技股份有限公司	将白细胞介素-10用于治疗疾病和病症的方法
CN104725484B (zh) *	2013-12-19	2018-03-13	中国科学院微生物研究所	一种糖基化多肽及其制备方法和其应用
EP3119412A1 (fr)	2014-03-21	2017-01-25	Boreal Invest	Nanofiltration finale de compositions de protéines solubilisées en vue de l'élimination d'agrégats immunogènes
CN106573072A (zh)	2014-06-02	2017-04-19	阿尔莫生物科技股份有限公司	降低血清胆固醇的方法
MX2017004983A (es)	2014-10-22	2017-11-13	Armo Biosciences Inc	Metodos para usar interleucina 10 para tratar enfermedades y trastornos.
CN104372021A (zh) *	2014-11-05	2015-02-25	太仓思源生物医药有限公司	人白细胞介素-2蛋白质的制备方法
WO2016126615A1 (fr)	2015-02-03	2016-08-11	Armo Biosciences, Inc.	Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
JP7121496B2 (ja)	2015-05-28	2022-08-18	アルモ・バイオサイエンシーズ・インコーポレイテッド	癌治療で使用するためのペグ化インターロイキン－１０
CN114853873B (zh)	2015-06-11	2025-01-28	格纳西尼有限公司	经修饰的白细胞介素-7蛋白及其用途
AU2016341402B2 (en)	2015-10-23	2020-08-27	Apogenix Ag	Single-chain GITR-receptor agonist proteins
KR102386735B1 (ko)	2015-11-06	2022-04-14	주식회사 제넥신	변형된 인터루킨-7 융합 단백질의 제형
WO2017095191A1 (fr) *	2015-12-04	2017-06-08	주식회사 제넥신	Composition pharmaceutique comprenant une protéine de fusion d'interleukine 7 fusionnés avec fc d'immunoglobuline pour la prévention ou le traitement de maladies causées par le papillomavirus humain
US11357827B2 (en)	2015-12-04	2022-06-14	Genexine, Inc.	Method for preventing or treating influenza virus infection using pharmaceutical composition comprising immunoglobulin Fc-fused interleukin-7 fusion protein
CN107759697B (zh) *	2016-08-19	2023-03-24	安源医药科技（上海）有限公司	制备融合蛋白的方法
IL273202B2 (en)	2017-09-11	2024-08-01	Univ Monash	Binding proteins to the human thrombin receptor, par4
WO2019144945A1 (fr)	2018-01-25	2019-08-01	I-Mab	Anticorps anti-pd-l1 et fusions d'il-7
CA3119341A1 (fr)	2018-11-16	2020-05-22	Neoimmunetech, Inc.	Methode de traitement d'une tumeur au moyen de l'association de la proteine il-7 et d'un inhibiteur de point de controle immunitaire
CN113614109A (zh)	2018-12-21	2021-11-05	Ose免疫疗法公司	双功能抗pd-1/il-7分子
AU2020334924A1 (en) *	2019-08-22	2022-04-07	The Regents Of The University Of California	UBE3A for the treatment of Angelman syndrome
AU2020383176B2 (en) *	2019-11-15	2023-10-19	Genexine, Inc.	Fusion protein including modified interleukin-7 and TGF beta receptor II and use thereof
JP2023512456A (ja)	2020-01-13	2023-03-27	ネオイミューンテック，インコーポレイテッド	Ｉｌ－７タンパク質と二重特異性抗体の組み合わせで腫瘍を治療する方法
JP2023512657A (ja)	2020-02-05	2023-03-28	ワシントン・ユニバーシティ	Ｉｌ－７タンパク質とｃａｒ保有免疫細胞の組み合わせで固形腫瘍を治療する方法
US20230398184A1 (en)	2020-10-26	2023-12-14	Neoimmunetech, Inc.	Methods of inducing stem cell mobilization
WO2022094475A1 (fr)	2020-11-02	2022-05-05	Neoimmunetech, Inc.	Utilisation de l'interleukine-7 pour le traitement du coronavirus
IL302482A (en)	2020-11-05	2023-06-01	Neoimmunetech Inc	Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
WO2022117569A1 (fr)	2020-12-02	2022-06-09	Oncurious Nv	Anticorps antagoniste de ccr8 en combinaison avec un anticorps agoniste du récepteur bêta de la lymphotoxine en thérapie contre le cancer
CN113817043B (zh) *	2021-09-22	2023-07-25	清华大学	制备活性铁调节激素的方法
JP2025501238A (ja)	2021-12-30	2025-01-17	ネオイミューンテック，インコーポレイテッド	Ｉｌ－７タンパク質とｖｅｇｆアンタゴニストの併用による腫瘍の治療方法
WO2023133595A2 (fr)	2022-01-10	2023-07-13	Sana Biotechnology, Inc.	Méthodes de dosage et d'administration ex vivo de particules lipidiques ou de vecteurs viraux ainsi que systèmes et utilisations associés
US20250222027A1 (en)	2022-04-01	2025-07-10	Sana Biotechnology, Inc.	Cytokine receptor agonist and viral vector combination therapies
KR20250089492A (ko)	2022-11-07	2025-06-18	네오이뮨텍, 인코퍼레이티드	비메틸화된 mgmt 프로모터를 갖는 종양의 치료 방법
WO2024150158A1 (fr)	2023-01-11	2024-07-18	Bright Peak Therapeutics Ag	Polypeptides il-7, immunocytokines les comprenant et leurs utilisations
WO2024261027A1 (fr)	2023-06-19	2024-12-26	Vector Biopharma Ag	Reciblage d'il-7 d'adénovirus pour une infection spécifique d'une cellule
CN117050178B (zh) *	2023-10-13	2024-01-12	北京百普赛斯生物科技股份有限公司	特异性检测il-7的抗体及应用
WO2025093541A1 (fr)	2023-10-31	2025-05-08	Ose Immunotherapeutics	Combinaison d'interleukine 7 et de vaccin antigénique associé à une tumeur

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA887773B (en) *	1987-10-26	1989-07-26	Immunex Corp	Interleukin-7
US5714585A (en) *	1987-10-26	1998-02-03	Sterling Winthrop, Inc.	Antibodies that are immunoreactive with interleukin-7
US4965195A (en)	1987-10-26	1990-10-23	Immunex Corp.	Interleukin-7
US5328988A (en) *	1987-10-26	1994-07-12	Immunex Corporation	Interleukin-7
US5153310A (en) *	1989-02-28	1992-10-06	Du Pont Merck Pharmaceutical Company	Il-2 analogs containing n-linked glycosylation sites
JP2004504016A (ja) *	2000-06-30	2004-02-12	マキシゲン・エイピーエス	ペプチド拡張されたグリコシル化ポリペプチド
EP1391513A1 (fr)	2002-08-08	2004-02-25	Cytheris	Substance médicamenteuse IL-7, composition comprenant IL-7, procédé de sa préparation et ses utilisations

2005
- 2005-07-20 EP EP05291556A patent/EP1746161A1/fr not_active Withdrawn
2006
- 2006-07-19 EP EP06795556A patent/EP1904635B1/fr active Active
- 2006-07-19 PT PT06795556T patent/PT1904635E/pt unknown
- 2006-07-19 EA EA200800368A patent/EA012802B1/ru not_active IP Right Cessation
- 2006-07-19 JP JP2008522097A patent/JP5685363B2/ja active Active
- 2006-07-19 US US11/996,176 patent/US7708985B2/en active Active
- 2006-07-19 CA CA2615562A patent/CA2615562C/fr active Active
- 2006-07-19 CN CN201610038940.9A patent/CN105647939A/zh active Pending
- 2006-07-19 CA CA2859145A patent/CA2859145C/fr active Active
- 2006-07-19 SI SI200631263T patent/SI1904635T1/sl unknown
- 2006-07-19 PL PL06795556T patent/PL1904635T3/pl unknown
- 2006-07-19 AT AT06795556T patent/ATE542901T1/de active
- 2006-07-19 NZ NZ564907A patent/NZ564907A/en not_active IP Right Cessation
- 2006-07-19 AU AU2006271315A patent/AU2006271315B2/en active Active
- 2006-07-19 WO PCT/IB2006/002663 patent/WO2007010401A2/fr not_active Ceased
- 2006-07-19 ES ES06795556T patent/ES2379732T3/es active Active
- 2006-07-19 DK DK06795556.7T patent/DK1904635T3/da active
- 2006-07-19 CN CN200680026503.XA patent/CN101228275B/zh not_active Expired - Fee Related
2007
- 2007-12-27 IL IL188480A patent/IL188480A0/en active IP Right Grant
2008
- 2008-01-03 NO NO20080045A patent/NO344802B1/no not_active IP Right Cessation
- 2008-01-18 ZA ZA200800533A patent/ZA200800533B/xx unknown
2010
- 2010-02-24 US US12/711,675 patent/US8034327B2/en active Active
2011
- 2011-08-24 US US13/216,331 patent/US8153114B2/en active Active
2012
- 2012-02-16 CY CY20121100161T patent/CY1112655T1/el unknown
2014
- 2014-10-01 JP JP2014202828A patent/JP2015057392A/ja active Pending

Also Published As

Publication number	Publication date
ZA200800533B (en)	2008-12-31
AU2006271315B2 (en)	2011-08-11
US20100196312A1 (en)	2010-08-05
AU2006271315A1 (en)	2007-01-25
CA2859145A1 (fr)	2007-01-25
WO2007010401A3 (fr)	2007-04-19
ES2379732T3 (es)	2012-05-03
IL188480A0 (en)	2008-04-13
EP1904635A2 (fr)	2008-04-02
US20080206190A1 (en)	2008-08-28
BRPI0613747A2 (pt)	2011-02-08
CA2615562A1 (fr)	2007-01-25
PL1904635T3 (pl)	2012-07-31
EA012802B1 (ru)	2009-12-30
CN105647939A (zh)	2016-06-08
CA2615562C (fr)	2014-11-04
JP2009501543A (ja)	2009-01-22
WO2007010401A2 (fr)	2007-01-25
SI1904635T1 (sl)	2012-10-30
PT1904635E (pt)	2012-03-06
ATE542901T1 (de)	2012-02-15
CN101228275A (zh)	2008-07-23
EP1904635B1 (fr)	2012-01-25
US20120016104A1 (en)	2012-01-19
US8153114B2 (en)	2012-04-10
DK1904635T3 (da)	2012-02-27
US7708985B2 (en)	2010-05-04
HK1115154A1 (en)	2008-11-21
EP1746161A1 (fr)	2007-01-24
EA200800368A1 (ru)	2008-06-30
JP5685363B2 (ja)	2015-03-18
JP2015057392A (ja)	2015-03-26
NZ564907A (en)	2011-09-30
NO20080045L (no)	2008-04-21
CN101228275B (zh)	2016-02-24
US8034327B2 (en)	2011-10-11
CA2859145C (fr)	2018-11-27
NO344802B1 (no)	2020-05-04

Publication	Publication Date	Title
CY1112655T1 (el)	2016-02-10	Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις
ES2353814T3 (es)	2011-03-07	Proteinas n-glicosiladas recombinantes de celulas procariotas.
MX2009012650A (es)	2010-02-18	Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
DE60330923D1 (de)	2010-02-25	Menschliche Koagulationsfaktor VII Polypeptide
MX2010005783A (es)	2010-08-10	Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
TNSN08064A1 (en)	2009-07-14	Albumin fusion proteins
MX2009002816A (es)	2009-05-28	Proteinas de fusion de albumina.
MX2011008094A (es)	2012-02-13	Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
WO2007104529A3 (fr)	2007-12-13	Séquences d'acides aminés dirigées contre il-6 et polypeptides incluant lesdites séquences dans le traitement de maladies et de troubles associés au signalement faisant intervenir il-6
MX2009004243A (es)	2009-05-14	Nuevas proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal.
DE60027409D1 (de)	2006-05-24	Glykosylierte leptinzusammensetzungen und zugehörige verfahren
DK0902085T3 (da)	2004-04-05	Rekombinant human erythropoietin med fordelagtig glycosyleringsprofil
IL212653A0 (en)	2011-07-31	Polypeptides of leishmania major and polynucleotides encoding same and vaccinal, therapeutical and diagnostic applications thereof
ATE501728T1 (de)	2011-04-15	Therapeutische verwendung von lpi, einem inhibitor des lectinwegs in staphylokokken bei entzündungskrankheiten
BR0308180A (pt)	2007-04-10	protéinas de superfìcie de leptospira
DE602007009797D1 (de)	2010-11-25	Antitumorheilmittel, Medikament, Zusammensetzung und Verwendung davon